Abstract
Mirogabalin （TarligeⓇ） has been approved for treating peripheral neuropathic pain; however, there are few clinical reports on its use in the treatment of orofacial pain. We investigated the therapeutic effect and side effects of mirogabalin on traumatic painful trigeminal neuropathy in the orofacial region, which was diagnosed based on the third edition of International Headache Society. Mirogabalin was prescribed to 9 patients with, painful post-traumatic trigeminal neuropathy who visited the Orofacial Pain Clinic of the Nihon University School of Dentistry; we recorded the male: female ratio and the age distribution, symptom duration, therapeutic effect, and side effects among these patients. The therapeutic effects, defined as alleviation in pain and pain intensity, were determined 3 months after mirogabalin was prescribed; the improvement rate for NRS was 40.6 ± 29.0％. Of the 9 cases, 4 reported side effects, namely, somnolence in 3 cases and weight gain and dizziness in one case. In conclusion, although mirogabalin treatment was effective in alleviating traumatic painful trigeminal neuropathy, it also exerted side effects. Therefore, caution should be exerted when using mirogabalin to treat peripheral neuropathy pain in the orofacial region; dose adjustment starting from a low dose is advised.
